Actively Recruiting
Randomized Study of Acetyl-L-carnitine Effects on Functional Disability and Biomarkers in ALS
Led by Mario Negri Institute for Pharmacological Research · Updated on 2026-10-06
246
Participants Needed
19
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase IIIII randomized, double-blind trial to evaluate acetyl-L-carnitine ALCAR in adults living with amyotrophic lateral sclerosis ALS. The main goal is to assess how two doses of ALCAR 1.5gday and 3gday affect the progression of functional disability measured by the ALSFRS-R scale. Secondary aims include examining ALCARs impact on respiratory function, quality of life, cognitive performance, survival, and disease biomarkers related to the drugs mechanisms. Participants will be randomly assigned to one of three groups ALCAR 1.5gday, ALCAR 3gday, or placebo, all alongside riluzole treatment. The study lasts 48 weeks, during which participants take the assigned medication three times daily. Follow-up visits occur at 4, 12, 24, 36, and 48 weeks to monitor health status, collect blood samples for biomarker testing, and perform various clinical assessments. Throughout the study, participants undergo evaluations including vital signs, neurological exams, respiratory tests, cognitive and quality of life assessments, and compliance checks. Researchers measure changes in functional disability, respiratory capacity, cognitive function, quality of life, biomarker levels, and survival rates. Safety is also monitored by recording adverse events. Participants will be followed until death after the trial period.
CONDITIONS
Brief Title
Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS
Research Team
E
Elisabetta Pupillo, PharmD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here